Investigation of the Number of Tests Required for Assaying Plasma Biomarkers Associated with Alzheimer's Disease Using Immunomagnetic Reduction.

Huei-Chun LiuHsin-Hsien ChenChia-Shin HoJui-Feng ChangChia-Chun LinMing-Jang ChiuTa-Fu ChenChaur-Jong HuSui-Hing YanYu SunShieh-Yueh Yang

Published in: Neurology and therapy (2021)

Based on this study, a single assay of Aβ1-40, Aβ1-42 and T-Tau, respectively, provides reliable results in terms of the measurement of that plasma biomarker.

Keyphrases

high throughput
cognitive decline
cerebrospinal fluid